Advanced Filters
noise

Male Pattern Baldness Clinical Trials

A listing of Male Pattern Baldness medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 296 clinical trials
L Lin Wang, Doctor

Combined Immunosuppression for Pediatric Crohn's Disease

This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.

6 - 18 years of age All Phase 4
M Mathurin FUMERY

Reliability of IUS in Crohn's Disease

Transabdominal intestinal ultrasound (IUS) is gaining acceptance as a point-of-care test to objectively assess disease activity in Crohn's disease (CD). In order to incorporate individual parameters in a future definition of transmural healing, and for the consistent application of IUS as a modality to assess treatment outcomes and establish therapeutic …

18 years of age All Phase N/A
C Cristiano Pagnini, MD, PhD

Clostridium Butyricum in Stenosing Crohn's Disease

Crohn's disease is a condition of unknown etiology with an immune-mediated pathogenesis. The subgroup of Crohn's disease with a stricturing phenotype represents a particular challenge for clinicians, as currently no effective medical therapies are available for the prevention or treatment of fibrosis. Autophagy is a key mechanism in the regulation …

18 - 85 years of age All Phase 1/2
J Jonathan Lagdameo

Autologous Stem Cell Transplant for Crohn's Disease

Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the stomach and intestines. Crohn's disease is a debilitating, incurable disease of immune cells; it affects almost 1 million people in the United States. CD is characterized by inflammation of the stomach and …

18 years of age All Phase 2
E Elina M Jokinen, PhD

Fecal Microbiota Transplantation in Postoperative Crohn's Disease

This pilot study aims to detect possible trends or signals suggesting efficacy of FMT on prevention of delay of POR, to determine the safety of FMT in post operative CD, and asses if a full randomised controlled trial is feasible in this setting. With microbiota analysis we aim to assess …

18 - 120 years of age All Phase N/A
D David Binion, MD

Autologous Stem Cell Transplantation for Crohn's Disease

The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.

10 - 60 years of age All Phase 1/2
B Biao Zou, doctor

Fecal Microbiota Transplantation in Pediatric Crohn's Disease

This study will test the safety and effectiveness of fecal microbiota transplantation (FMT) plus partial enteral nutrition (PEN) in refractory pediatric Crohn's disease (CD) who have failed conventional treatment

2 - 16 years of age All Phase N/A
A Amit Assa, MD

Post-Operative Crohn's Disease Outcome in Children

Objectives: To examine the effect of prophylaxis therapy on clinical and endoscopic disease recurrence in children with Crohn's Disease (CD) following ileo-cecal resection. Hypothesis: Post-operative pediatric patients treated with anti-Tumor necrosis factor (TNF) prophylaxis will demonstrate lower endoscopic recurrence rates at 1 year and lower clinical recurrence rates at 2 …

6 - 18 years of age All Phase N/A
B Byron Vaughn

Standardized Microbiota Transplant Therapy in Crohn's Disease

Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation (FMT) for the treatment of recurrent …

18 - 89 years of age All Phase 2

Risankizumab in Children With Crohn's Disease (RisaKids)

The goal of this observational study is to to prospectively explore the real life short (12 weeks) and longer term (54 weeks) clinical, biochemical and endoscopic outcomes of risankizumab in pediatric CD. This is a 1-year prospective multi-center cohort study of children commencing on risankizumab for pediatric CD with 2 …

6 - 18 years of age All Phase N/A

Simplify language using AI